Post-Operative Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The Post-Operative Pain pipeline market research report provides comprehensive information on the therapeutics under development for Post-Operative Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for PostOperative Pain and features dormant and discontinued projects.
What are the key targets in the Post-Operative Pain pipeline market?
The key targets in the Post-Operative Pain pipeline market are Mu Type Opioid Receptor, Prostaglandin G/H Synthase 2, Prostaglandin G/H Synthase 1, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Channel Protein Type 1 Subunit Alpha, Sodium Channel Protein Type 2 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sodium Channel Protein Type 4 Subunit Alpha, Sodium Channel Protein Type 5 Subunit Alpha, and Sodium Channel Protein Type 8 Subunit Alpha. Mu Type Opioid Receptor has the highest number of pipeline products in the Post-Operative Pain pipeline market.
Post-Operative Pain pipeline market, by targets
For more target insights, download a free report sample
What are the key MoA in the Post-Operative Pain pipeline market?
The key MoA in the Post-Operative Pain pipeline market are Mu Type Opioid Receptor Agonist, Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Sodium Channel Protein Type 10 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, Sodium Channel Protein Type 1 Subunit Alpha Blocker, Sodium Channel Protein Type 2 Subunit Alpha Blocker, Sodium Channel Protein Type 3 Subunit Alpha Blocker, Sodium Channel Protein Type 4 Subunit Alpha Blocker, Sodium Channel Protein Type 8 Subunit Alpha Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker.
Post-Operative Pain pipeline market, by MoA
For more MoA insights, download a free report sample
What are the key RoA in the Post-Operative Pain pipeline market?
The key RoA in the Post-Operative Pain pipeline market are Intravenous, Oral, Parenteral, Intravenous Bolus, Subcutaneous, Topical, Intramuscular, Sublingual, Intrathecal, and Ophthalmic. Intravenous has the highest number of pipeline products in the Post-Operative Pain pipeline market.
Post-Operative Pain pipeline market, by RoA
For more RoA insights, download a free report sample
What are the key molecule type in the Post-Operative Pain pipeline market?
The key molecule type in the Post-Operative Pain pipeline market are Small Molecule, Synthetic Peptide, Antisense Oligonucleotide, Aptamer, Gene Therapy, and Recombinant Protein. Small Molecule has the highest number of pipeline products in the Post-Operative Pain pipeline market.
Post-Operative Pain pipeline market, by molecule type
For more molecule type insights, download a free report sample
What are the key companies in the Post-Operative Pain pipeline market?
The key companies in the Post-Operative Pain pipeline market are Jiangsu Hengrui Medicine Co Ltd, Allay Therapeutics Inc, Nanjing Delova Biotech Co Ltd, Neumentum Inc, Vivozon Inc, Altus Formulation Inc, Grunenthal GmbH, Hefei Cosource Pharmaceutical Inc, Heron Therapeutics Inc, InSitu Biologics LLC, and Lumosa Therapeutics Co Ltd. Jiangsu Hengrui Medicine Co Ltd Jiangsu Hengrui Medicine Co Ltd.
Post-Operative Pain pipeline market, by companies
To know more about key companies, download a free report sample
Market report overview
Key targets | Mu Type Opioid Receptor, Prostaglandin G/H Synthase 2, Prostaglandin G/H Synthase 1, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Channel Protein Type 1 Subunit Alpha, Sodium Channel Protein Type 2 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sodium Channel Protein Type 4 Subunit Alpha, Sodium Channel Protein Type 5 Subunit Alpha, and Sodium Channel Protein Type 8 Subunit Alpha |
Key MoA | Mu Type Opioid Receptor Agonist, Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Sodium Channel Protein Type 10 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, Sodium Channel Protein Type 1 Subunit Alpha Blocker, Sodium Channel Protein Type 2 Subunit Alpha Blocker, Sodium Channel Protein Type 3 Subunit Alpha Blocker, Sodium Channel Protein Type 4 Subunit Alpha Blocker, Sodium Channel Protein Type 8 Subunit Alpha Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker |
Key RoA | Intravenous, Oral, Parenteral, Intravenous Bolus, Subcutaneous, Topical, Intramuscular, Sublingual, Intrathecal, and Ophthalmic |
Key molecule type | Small Molecule, Synthetic Peptide, Antisense Oligonucleotide, Aptamer, Gene Therapy, and Recombinant Protein |
Key companies | Jiangsu Hengrui Medicine Co Ltd, Allay Therapeutics Inc, Nanjing Delova Biotech Co Ltd, Neumentum Inc, Vivozon Inc, Altus Formulation Inc, Grunenthal GmbH, Hefei Cosource Pharmaceutical Inc, Heron Therapeutics Inc, InSitu Biologics LLC, and Lumosa Therapeutics Co Ltd. Jiangsu Hengrui Medicine Co Ltd Jiangsu Hengrui Medicine Co Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Operative Pain (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Operative Pain (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Operative Pain (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Operative Pain (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Operative Pain (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Operative Pain (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Operative Pain (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AcelRx Pharmaceuticals Inc
Adare Pharma Solutions
Algomedix Inc
Allay Therapeutics Inc
Altus Formulation Inc
AmacaThera Inc
Andros Pharmaceuticals Co Ltd
AngioChem Inc
Antibe Therapeutics Inc
Bayer AG
Beijing Join Chain Medicine Co Ltd
Benuvia Therapeutics Inc
Brainfarma Chemical and Pharmaceutical Industry SA
Cali Pharmaceuticals LLC
Camurus AB
Cara Therapeutics Inc
Cellix Bio Pvt Ltd
Chromocell Corp
Clexio Biosciences Ltd
Concentric Analgesics Inc
Cytogel Pharma LLC
Daewoong Pharmaceutical Co Ltd
Dompe Farmaceutici SpA
Douleur Therapeutics Inc
Eliem Therapeutics Inc
Ethismos Research Inc
Euclises Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc
Eurofarma Laboratorios SA
Flexion Therapeutics Inc
Fujimoto Pharmaceutical Corp
G2GBIO Inc
Grunenthal GmbH
Guangdong Jiabo Pharmaceutical Co Ltd
Hana Pharm Co Ltd
Hefei Cosource Pharmaceutical Inc
Heron Therapeutics Inc
Hyloris Pharmaceuticals SA
IACTA Pharmaceuticals Inc
InSitu Biologics LLC
Insys Therapeutics Inc (Inactive)
InterK Peptide Therapeutics Ltd
Ionis Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Huatai Chenguang Pharmaceutical Co Ltd
Liquidia Technologies Inc
Lumosa Therapeutics Co Ltd
Luye Pharma Group Ltd
Medical Developments International Ltd
MedinCell SA
Mundipharma International Ltd
Nang Kuang Pharmaceutical Co Ltd
Nanjing Delova Biotech Co Ltd
Nanjing Heron Pharmaceutical Science and Technology Co Ltd
Neumentum Inc
Neurocarrus Inc
NeuroPn Therapeutics LLC
Nevakar Injectables Inc
Ocular Therapeutix Inc
Pacira BioSciences Inc
PainReform Ltd
Pharmazz Inc
PhytoHealth Corp
PolyPid Ltd
Revogenex Inc
RHNanopharmacuticals LLC
Rottapharm Biotech Srl
Sedor Pharmaceuticals LLC
Seelos Therapeutics, Inc.
Serina Therapeutics Inc
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sichuan Haisco Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
SiteOne Therapeutics Inc
Sonoran Biosciences Inc
Sotex Pharm Firm
Stragen New Molecules
Taiwan Liposome Co Ltd
Teikoku Pharma USA Inc
Theracaine LLC
Trevena Inc
Tris Pharma Inc
Vertex Pharmaceuticals Inc
Viatris Inc
Virpax Pharmaceuticals Inc
Vivozon Inc
Xgene Pharmaceutical Inc
Xigen SA
Yichang Humanwell Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Post-Operative Pain pipeline market?
The key targets in the Post-Operative Pain pipeline market are Mu Type Opioid Receptor, Prostaglandin G/H Synthase 2, Prostaglandin G/H Synthase 1, Sodium Channel Protein Type 10 Subunit Alpha, Sodium Channel Protein Type 9 Subunit Alpha, Sodium Channel Protein Type 1 Subunit Alpha, Sodium Channel Protein Type 2 Subunit Alpha, Sodium Channel Protein Type 3 Subunit Alpha, Sodium Channel Protein Type 4 Subunit Alpha, Sodium Channel Protein Type 5 Subunit Alpha, and Sodium Channel Protein Type 8 Subunit Alpha. Mu Type Opioid Receptor has the highest number of pipeline products in the Post-Operative Pain pipeline market.
-
What are the key MoA in the Post-Operative Pain pipeline market?
The key MoA in the Post-Operative Pain pipeline market are Mu Type Opioid Receptor Agonist, Prostaglandin G/H Synthase 2 Inhibitor, Prostaglandin G/H Synthase 1 Inhibitor, Sodium Channel Protein Type 10 Subunit Alpha Blocker, Sodium Channel Protein Type 9 Subunit Alpha Blocker, Sodium Channel Protein Type 1 Subunit Alpha Blocker, Sodium Channel Protein Type 2 Subunit Alpha Blocker, Sodium Channel Protein Type 3 Subunit Alpha Blocker, Sodium Channel Protein Type 4 Subunit Alpha Blocker, Sodium Channel Protein Type 8 Subunit Alpha Blocker, and Sodium Channel Protein Type 5 Subunit Alpha Blocker.
-
What are the key RoA in the Post-Operative Pain pipeline market?
The key RoA in the Post-Operative Pain pipeline market are Intravenous, Oral, Parenteral, Intravenous Bolus, Subcutaneous, Topical, Intramuscular, Sublingual, Intrathecal, and Ophthalmic. Intravenous has the highest number of pipeline products in the Post-Operative Pain pipeline market.
-
What are the key molecule type in the Post-Operative Pain pipeline market?
The key molecule type in the Post-Operative Pain pipeline market are Small Molecule, Synthetic Peptide, Antisense Oligonucleotide, Aptamer, Gene Therapy, and Recombinant Protein. Small Molecule has the highest number of pipeline products in the Post-Operative Pain pipeline market.
-
What are the key companies in the Post-Operative Pain pipeline market?
The key companies in the Post-Operative Pain pipeline market are Jiangsu Hengrui Medicine Co Ltd, Allay Therapeutics Inc, Nanjing Delova Biotech Co Ltd, Neumentum Inc, Vivozon Inc, Altus Formulation Inc, Grunenthal GmbH, Hefei Cosource Pharmaceutical Inc, Heron Therapeutics Inc, InSitu Biologics LLC, and Lumosa Therapeutics Co Ltd. Jiangsu Hengrui Medicine Co Ltd Jiangsu Hengrui Medicine Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.